Cyclo Therapeutics, Inc.
CYTH, CYTHWHealthcare · Healthcare · Non-accelerated filer<br>Smaller reporting company · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | |
|---|---|---|---|---|---|---|
| Revenue | $1.1M | $1.4M | $1.6M | $903,376 | $1.0M | $1.0M |
| Operating income | −$20.1M | −$15.6M | −$14.3M | −$9.0M | −$7.5M | −$4.3M |
| Net income | −$20.1M | −$15.5M | −$14.3M | −$8.9M | −$7.5M | −$4.3M |
| Total assets | $13.2M | $4.2M | $19.5M | $14.2M | $4.1M | $2.9M |
| Total liabilities | — | — | — | — | — | — |
| Equity | $4.8M | $734,544 | $15.7M | $10.5M | $935,982 | $992,524 |
| EPS (diluted) | $-1.23 | $-1.83 | $-2.24 | — | — | — |
| Shares out. | 10.6M | 8.4M | 6.3M | 121.7M | 91.3M | 73.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- −1862.7%
- Net margin
- −1863.4%
- Return on equity
- −421.6%
- Return on assets
- −151.4%
- Return on capital (ROCE)
- −419.5%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $0.45
- Revenue growth (YoY)
- −21.8%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Accruals / assets
- −29.2%clean
- Piotroski F-Score
- 3/8weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 4 warning● 1 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Apr 2, 2018
- NT 10-Qmissed a reporting deadline ↗May 16, 2012
- NT 10-Qmissed a reporting deadline ↗Nov 14, 2011
- NT 10-Qmissed a reporting deadline ↗Nov 16, 2010
- NT 10-Kmissed a reporting deadline ↗Apr 1, 2008
- NT 10-Qmissed a reporting deadline ↗Aug 13, 2004
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Conkling WilliamDirector | Feb 27, 2025 | Grant | 27,654 | $0.00 |
| Wong VivienDirector | Feb 27, 2025 | Grant | 25,140 | $0.00 |
| Cross ShawnDirector | Feb 27, 2025 | Grant | 28,597 | $0.00 |
| Toig Randall M.Director | Feb 27, 2025 | Grant | 33,311 | $0.00 |
| Strattan Ce RickDirector | Feb 27, 2025 | Grant | 30,169 | $0.00 |
| Ostronic Francis PatrickDirector | Feb 27, 2025 | Grant | 70,329 | $0.00 |
| Sieger MarkusDirector | Feb 27, 2025 | Grant | 58,138 | $0.00 |
| Shanahan William SDirector | Feb 27, 2025 | Grant | 25,140 | $0.00 |
| Rafael Holdings, Inc.10% owner | Dec 23, 2024 | Conversion | 4.0M | $0.63 |
| Conkling WilliamDirector | Nov 15, 2024 | Grant | 16,660 | $0.00 |
| Cross ShawnDirector | Nov 15, 2024 | Grant | 17,228 | $0.00 |
| Shanahan William SDirector | Nov 15, 2024 | Grant | 15,145 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Regulation FD disclosureMar 26, 2025
- Shareholder voteMar 24, 2025
- Entered a material agreement · New financial obligationMar 6, 2025
- Entered a material agreement · New financial obligationFeb 4, 2025
- Delisting / listing-standard noticeJan 13, 2025
- Entered a material agreement · New financial obligationJan 3, 2025
- Entered a material agreement · New financial obligation · Other material eventDec 23, 2024
- Entered a material agreement · New financial obligationDec 5, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 15-12GFORM 15-12GApr 7, 2025
- 25-NSEMar 26, 2025
- 8-KFORM 8-KMar 26, 2025
- 8-KFORM 8-KMar 24, 2025
- 8-KFORM 8-KMar 6, 2025
- 4FORM 4Mar 3, 2025
- 4FORM 4Mar 3, 2025
- 4FORM 4Mar 3, 2025
- 4FORM 4Mar 3, 2025
- 4FORM 4Mar 3, 2025
- 4FORM 4Mar 3, 2025
- 4FORM 4Mar 3, 2025
- 4FORM 4Feb 28, 2025
- UPLOADFeb 14, 2025
- 8-KFORM 8-KFeb 4, 2025
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.